CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AziFlu project focuses on developing a new class of anti-influenza drugs that irreversibly inhibit influenza neuraminidases. These compounds aim to provide more effective treatment options for flu infections compared to existing medications, with potential applications in both treatment and prevention.
Influenza neuraminidases are the primary target for anti-influenza small molecule drugs and are retaining glycosidases that form a transient covalent intermediate during substrate hydrolysis.
Oseltamivir (Tamiflu) and Zanamivir (Relenza), the two small-molecule anti-influenza drugs used primarily for early onset treatment of flu infections, inhibit influenza neuraminidases competitively (and thus reversibly).
The AziFlu ERC PoC proposal is rooted in our finding that N-acyl Oseltamivir aziridines…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
